Femasys to Participate in the Women’s Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET
Femasys Inc. (NASDAQ: FEMY) has been invited to present at the Women’s Health Panel Discussion hosted by Maxim Group LLC on July 13, 2022, at 11:00 a.m. ET. Kathy Lee-Sepsick, CEO, will discuss the implications of the Supreme Court's decision to overturn Roe v. Wade on women's health and contraception. This virtual event will spotlight the critical issues in women's reproductive health, bringing together key industry players. Femasys is known for its innovations in minimally invasive reproductive health technologies, including FemBloc and FemaSeed.
- None.
- None.
ATLANTA, July 11, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company has been invited to present at the Women’s Health Panel Discussion, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, July 13th, 2022 at 11:00 a.m. ET.
During this on-demand virtual event, Kathy Lee-Sepsick, Founder, President and Chief Executive Officer, will participate in the panel detailed below:
Panel title: “A tipping point in women's health - does the SCOTUS outcome change the paradigm in contraception?”
Panel Description: “This is the most critical time in women's health in decades, perhaps ever. The Supreme Court decision to overturn Roe v. Wade continues to reverberate across the country. As a result, the discussion around contraception, contraceptive options, access, issues with pharmacy benefit managers and women's reproductive health as a space, have all accelerated to the forefront of discussion from the media and general public, all the way to the White House. Please Join us July 13, 2022, at 11:00 am for a panel discussion with key players in the contraception space; Agile Therapeutics, Dare Bioscience and Femasys.”
Panel day/ time: Wednesday, July 13th 2022 at 11 a.m. ET.
This conference will be live on M-Vest. To listen to the panel discussion, register to become an M-Vest member here.
About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in the United States. Femasys is also advancing FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com
Media
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.com
FAQ
When is the Women’s Health Panel Discussion featuring Femasys?
What topics will Femasys discuss at the July 13 panel?
Who is presenting for Femasys at the panel discussion?
How can I listen to the Femasys panel discussion on women's health?
What products is Femasys known for?
